Amalgamated Bank’s Aldeyra Therapeutics ALDX Stock Holding History

Amalgamated Bank’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,705	Closed	-$9K	–	1658
2025 Q4	$9K	Buy	1,705 +134	+9%	+$688	﹤0.01%	2448
2025 Q3	$8K	Hold	1,571	–	–	﹤0.01%	2546
2025 Q2	$6K	Hold	1,571	–	–	﹤0.01%	2626
2025 Q1	$9K	Hold	1,571	–	–	﹤0.01%	2394
2024 Q4	$8K	Hold	1,571	–	–	﹤0.01%	2520
2024 Q3	$8K	Hold	1,571	–	–	﹤0.01%	2531
2024 Q2	$5K	Hold	1,571	–	–	﹤0.01%	2737
2024 Q1	$5K	Sell	1,571 -5,023	-76%	-$16.5K	﹤0.01%	2687
2023 Q4	$23K	Sell	6,594 -467	-7%	-$1.44K	﹤0.01%	2576
2023 Q3	$47K	Hold	7,061	–	–	﹤0.01%	2276
2023 Q2	$59K	Buy	+7,061	New	+$69.6K	﹤0.01%	2252
2022 Q2	–	Sell	-7,928	Closed	-$35K	–	3029
2022 Q1	$35K	Buy	+7,928	New	+$31.6K	﹤0.01%	2619

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Amalgamated Bank's ALDX Position: Q1 2026 in Review

Amalgamated Bank sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 1,705 shares — an estimated $9K sold.

Amalgamated Bank first reported a position in ALDX in Q1 2022 and held it in 12 quarters. The position peaked at $59K in Q2 2023. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Amalgamated Bank reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
Amalgamated Bank sold 1,705 Aldeyra Therapeutics shares in Q1 2026, an estimated $9K.
Amalgamated Bank first reported a position in Aldeyra Therapeutics in Q1 2022 and held it in 12 quarters.
Amalgamated Bank's Aldeyra Therapeutics position peaked at $59K in Q2 2023.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.